Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Gedatolisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 19/20 | 1.00 |
| ▸ | PIK3CA known ✓ | P42336 | 18/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 8/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 3/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 2/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 0.78 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gedatolisib SCHEMBL20765097 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL32727 | 0.97 | MTOR (0.95) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL20765154 | 0.96 | MTOR (0.93) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL32828 | 0.96 | MTOR (0.93) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL32433 | 0.95 | MTOR (0.91) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL29047454 | 0.95 | MTOR (0.90) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL32600 | 0.94 | PIK3CA (0.90) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL32634 | 0.94 | PIK3CA (0.90) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL32250 | 0.94 | PIK3CA (0.90) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL20765101 | 0.94 | MTOR (0.88) | MTORPIK3CAPIK3CGPIK3CBPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3603 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4735643-A1 | METHODS FOR EARLY DETECTION OF CANCER | Guardant Health, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260120878-A1 | METHODS FOR EARLY DETECTION OF CANCER | GUARDANT HEALTH INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-12576069-B2 | Compositions and methods for treating slow-flow vascular malformations | YALE UNIVERSITY (US) | 2026-03-17 | — | — | US | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| US-8748421-B2 | Triazine compounds as P13 kinase and MTOR inhibitors | WYETH LLC (US) | 2014-06-10 | — | — | US | claimed |
| US-20130315865-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | PFIZER INC. (US) | 2013-11-28 | — | — | US | claimed |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2013-01-03 | — | — | US | claimed |
| US-8217036-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2012-07-10 | — | — | US | claimed |
| US-8039469-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2011-10-18 | — | — | US | claimed |
| JP-2011522802-A | — | — | 2011-08-04 | — | — | JP | claimed |
| CN-102036995-A | Triazine compounds as inhibitors of PI3 kinase and mTOR | WYETH CORP | 2011-04-27 | — | — | CN | claimed |
| EP-2294072-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2011-03-16 | — | — | EP | claimed |
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-11-26 | — | — | US | claimed |
| WO-2009143313-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH (US) | 2009-11-26 | — | — | WO | claimed |